Stocks to buy today: Wipro, Coal India among top 9 trading ideas for 20 December 2024

 20 Dec 2024 09:04 AM

The Indian market is expected to consolidate on Friday, influenced by global cues. Nifty futures closed 0.97% lower at 24,021. Options data suggests a trading range between 23,400–24,400, with immediate levels at 23,700–24,200. Experts recommend short-term stock buys including Wipro, SAIL, Coal India, Apollo Hospitals, LIC, Abbott India, Infosys, Lupin, and Muthoot Finance.

Lupin 0.55% as Sensex

 19 Dec 2024 10:05 AM

The stock traded at a P/E multiple of 36.49, while the price-to-book value ratio stood at 5.16.

Lupin shares in focus after FDA approval for generic HIV tablets

 19 Dec 2024 09:12 AM

Indian pharmaceutical giant Lupin gained US FDA approval for its generic version of Gilead Sciences' HIV drug Descovy. This win grants Lupin 180 days of shared exclusivity in the US market, a significant boost for the company. The generic drug will be produced at Lupin's Nagpur facility. Lupin's shares saw a 2.

LUPIN: CO GOT APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS 200 MG/25 MG, TO MARKET A GENERIC EQUIVALENT OF DESCOVY® TABLETS, 200 MG/25 MG OF GILEAD SCIENCES, INC. || LUPIN IS ONE OF THE FIRST ANDA APPLICANTS AND IS ELIGIBLE FOR 180 DAYS OF SHARED GENERIC EXCLUSIVITY

 18 Dec 2024 06:15 PM

LUPIN: CO GOT APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS 200 MG/25 MG, TO MARKET A GENERIC EQUIVALENT OF DESCOVY® TABLETS, 200 MG/25 MG OF GILEAD SCIENCES, INC. || LUPIN IS ONE OF THE FIRST ANDA APPLICANTS AND IS ELIGIBLE FOR 180 DAYS OF SHARED GENERIC EXCLUSIVITY

Lupin shares 1.66% as Sensex falls

 18 Dec 2024 10:00 AM

A total of 3,492 shares changed hands on the counter till 09:59AM (IST)

Lupin shares 0.24% as Sensex falls

 17 Dec 2024 10:50 AM

A total of 1,625 shares changed hands on the counter till 10:50AM (IST)

Lupin shares 0.62% as Nifty falls

 16 Dec 2024 12:53 PM

The stock quoted a 52-week high price of Rs 2312.00 and low of Rs 1200.35.

Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolio

 16 Dec 2024 09:11 AM

Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster its diabetes portfolio in India. The transfer will be complete by March next year. Lupin has been co-marketing these drugs since 2016 and 2018, respectively. This acquisition strengthens Lupin's commitment to providing affordable diabetes medications.

LUPIN: CO SAYS TRADEMARK RIGHTS TO BE TRANSFERRED TO LUPIN BY MARCH

 13 Dec 2024 05:22 PM

LUPIN: CO SAYS TRADEMARK RIGHTS TO BE TRANSFERRED TO LUPIN BY MARCH

LUPIN: CO ACQUIRES 3 TRADEMARKS FROM BOEHRINGER INGELHEIM TO STRENGTHEN DIABETES PORTFOLIO || GIBTULIO®, GIBTULIO MET® AND AJADUO® ARE KEY COMPONENTS FOR DIABETES TREATMENT

 13 Dec 2024 05:21 PM

LUPIN: CO ACQUIRES 3 TRADEMARKS FROM BOEHRINGER INGELHEIM TO STRENGTHEN DIABETES PORTFOLIO || GIBTULIO®, GIBTULIO MET® AND AJADUO® ARE KEY COMPONENTS FOR DIABETES TREATMENT